IL1B and head and neck squamous cell carcinoma: However our findings of activating IL-1 ligands being associated with more favorable survival outcomes in cetuximab-treated HNSCC patients (Fig. 2d,e) challenge the current understanding of the pro-survival role of IL-1 signaling in tumor biology.